Sermorelin Injection
A growth hormone-releasing peptide that supports deeper sleep, faster recovery and lean muscle by working with your body's own rhythm.
Injection
from $179/mo
Injected under the skin · 5 days a week
Research peptideImmune
LL-37
A research peptide derived from human antimicrobial proteins, studied for immune modulation and inflammation, used to support immune and skin health.
- Derived from your own immune system's antimicrobial peptide
- Early research in humans; most evidence is laboratory
- Subcutaneous injection, dosed by your physician
- Monthly$299/mo
- Every 3 months$717 billed up front$239/mo
- Every 6 monthsBest value$1,254 billed up front$209/mo
- Free, discreet shipping
- Licensed U.S. pharmacy
- Board-certified physicians
Disclaimer: Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not FDA-approved brand-name products.
- How
- Injected under the skin
- How often
- 5 days a week
- Each shipment
- 1 vial
- Strength
- 2 mg/mL
What is LL-37?
(cathelicidin-related antimicrobial peptide)
LL-37 is a fragment of human cathelicidin, an antimicrobial peptide your immune system makes. Beyond killing bacteria directly, it modulates immune signaling and may reduce excessive inflammation. It is prescribed off-label based on preclinical evidence and growing clinical interest, not approved trials.
What's in it
- LL-37Antimicrobial peptide
Early
human evidence for LL-37 in immune and skin applications
Most research is in cell cultures and animal models. Injectable LL-37 is prescribed off-label at your physician's discretion.
Is it right for you?
Who it's for
Adults who want an immune peptide and have no psoriasis or rosacea.
What sets it apart
An antimicrobial peptide the body makes itself. Injecting it has not been studied in trials.
Worth knowing before you start
High LL-37 in the skin is part of psoriasis and rosacea. If either flares, stop.
What to expect
Slower feedback
early-stage therapies take time and close monitoring
Individual response
outcomes vary widely because evidence is limited
Physician partnership
your role is to communicate closely at every check-in
Informed choice
you understand the evidence gap before starting
How research peptides work
Day 1
A US-licensed physician reviews your goal, health history and reasons to try this early-stage peptide. You discuss the evidence and the unknowns together.
1Week 1
A small subcutaneous injection, usually in the abdomen or near the site you're treating. Most people find the routine comfortable within days.
2Week 2–4
Signaling and recovery processes begin. Many report improved energy or easier movement, depending on the peptide.
3Month 2+
Your physician checks in, adjusts dose if needed, and follows relevant labs (IGF-1, immune markers, etc.). Tell them everything you notice.
4
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
How you use it
This is the starting dose the pharmacy prints on the label. Your physician sets yours and adjusts it with you.
- How
- Injected under the skin
- Dose
- 20 units (0.4 mg)
- How often
- 5 days a week
- Each shipment
- 1 vial
- Pharmacy label
- Inject 20 units (0.4 mg) subcutaneously once daily 5 days per week for 4 weeks. Discard any remaining medication.
A sample week
- M
- T
- W
- T
- F
- S
- S
5 days a week
The science of research peptides
In laboratory studies, LL-37 activates immune cells, reduces inflammatory cytokines, and has antimicrobial effects. It is being explored for skin and wound healing.
Human clinical data are very limited. Your physician explains the early stage of this evidence and follows how you respond at check-ins.
Learn moreImportant safety information and common side effects
Research peptides are prescribed off-label and carry more uncertainty than established therapies. Common, mild effects include redness, itching or a bump at the injection site, headache, or flushing in the first days. Because these peptides support cell growth or immune signaling, they are not prescribed with an active cancer, a cancer under evaluation, or during pregnancy or breastfeeding. Some (IGF-1) require careful glucose monitoring. Tell your physician about every medication you take, every supplement, and your complete health history, including any autoimmune conditions. Stop and seek care for hives, swelling of the face or lips, or trouble breathing.
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Dispensed by a US-licensed compounding pharmacy
- Unlimited protocol adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Reviewed by our in-house physicians
How it works
1.Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
2.Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
3.Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
LL-37 educational content reviewed by our physician
Scott Nass, MDDoctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
Frequently asked questions
How do I use LL-37?
Injected under the skin, 5 days a week. The starting prescription is 20 units (0.4 mg) each time. Your physician sets your own dose and it is printed on your label.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
Who uses LL-37?
People interested in immune support or with persistent skin or inflammatory conditions who want to explore an emerging option. Your physician reviews your history and decides whether to trial it; it is not prescribed with active infection without careful discussion.
Why are these off-label?
Off-label means not FDA-approved for these specific uses, but prescribed by physicians based on preclinical evidence and clinical experience. It is common in medical practice; your physician explains the evidence and the gaps.
How often do I take it?
Usually a small subcutaneous injection once daily or a few times a week, depending on the peptide. Your physician sets the schedule and adjusts it as needed. The kit includes everything.
What is the evidence really like?
Honest answer: early. Preclinical and animal data are promising; human data are limited or absent. Your physician explains this plainly and monitors you closely. If you prefer established therapies, tell them.
Research peptides require partnership.
Tesamorelin
A peptide that targets stubborn abdominal fat and supports a leaner body composition, prescribed and monitored by a licensed clinician.
Injection
from $179/mo
Sermorelin Troches
The same growth hormone-releasing peptide as a dissolving troche, for people who would rather skip injections.
Troche
from $179/mo
CJC-1295 / Ipamorelin
Two peptides that prompt your pituitary to release your own growth hormone, used for deeper sleep, recovery and body composition. Prescribed and dosed by a licensed physician.
Injection
from $229/mo
The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Individual results vary.
Sources
- 1
Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.
Cells, 2020 - 2
Unique features of human cathelicidin LL-37.
Biofactors, 2015 - 3
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Curr Rev Musculoskelet Med, 2025 - 4
Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV.
N Engl J Med, 2007 - 5
Ipamorelin, the first selective growth hormone secretagogue.
Eur J Endocrinol, 1998 - 6
Thymosin alpha 1: A comprehensive review of the literature.
World J Virol, 2020
LL-37from $209/mo